Oncothyreon (ONTY) agrees to pay Array BioPharma (ARRY) $10M as part of a deal to collaborate on...

|By:, SA News Editor

Oncothyreon (ONTY) agrees to pay Array BioPharma (ARRY) $10M as part of a deal to collaborate on developing the latter's ARRY-380 molecule for treating breast and other cancers. Oncothyreon is raising the $10M by selling 5M shares and warrants for another 5M shares to BVF Partners.